Pune, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Antibody Drug Conjugates [ADC] Market Size & Growth Analysis:
“According to SNS Insider Research, The Antibody Drug Conjugates (ADC) Market size was valued at USD 8.71 billion in 2023 and is expected to reach USD 24.70 billion by 2032, growing at a CAGR of 12.30% over the forecast period 2024-2032.”
Antibody Drug Conjugates represent a significant advancement in targeted chemotherapy, merging the specificity of antibodies with the potency of cytotoxic drugs to accurately target and destroy cancer cells. Since the approval of the first ADC in 2000, the field has experienced substantial growth, with technological innovations driving new developments. ADCs are now integral to the treatment of various cancer subtypes, such as HER2-positive, hormone receptor-positive, triple-negative breast cancer, and urothelial cancer.
The recent acceptance of datopotamab deruxtecan by the FDA for treating metastatic HR-positive, and HER2-negative breast cancer highlights the ongoing momentum in this field. The growing incidence of cancer, with the increasing number of survivors, underscores the urgent need for advancements in cancer therapy. With over 160 ADCs in development as of April 2024, and substantial investments from pharmaceutical companies, the ADC market is poised for significant expansion.
Get a Sample Report of Antibody Drug Conjugates [ADC] Market@ https://www.snsinsider.com/sample-request/4421
Major Players Analysis Listed in this Report are:
- Zydus Group
- F. Hoffmann-La Roche Ltd
- Astellas Pharma Inc
- ImmunoGen, Inc.
- Daiichi Sankyo Company, Limited
- Gilead Sciences, Inc.
- ADC Therapeutics SA
- Takeda Pharmaceutical Company Limited
- AstraZeneca
- Seagen Inc.
- Pfizer Inc.
- Other Players
Antibody Drug Conjugates [ADC] Market Report Scope:
| Report Attributes | Details |
| Market Size in 2023 | US$ 8.71 billion |
| Market Size by 2032 | US$ 24.70 Billion |
| CAGR | CAGR of 12.30% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Key Growth Drivers | • Improved efficacy •Clinical trial success •Expanding treatment options • The Rise of Targeted Therapies: T-DXd in Uterine Cancer |
“Pioneering Next-Generation Cancer Therapies with Enhanced Efficacy and Precision"
Antibody Drug Conjugates (ADCs) are at the forefront of the next generation of cancer therapies, offering improved efficacy and expanding treatment options for patients. The advancements in antibody engineering and linker technology have led to the creation of highly potent ADCs, addressing previous challenges such as weak linkers and imprecise targeting. These innovations have resulted in ADCs that are more effective and specific, reducing the collateral damage to healthy tissues.
Do you have any specific queries or need any customization research on Antibody Drug Conjugates [ADC] Market, Make an Enquiry Now@ https://www.snsinsider.com/enquiry/4421
Recent clinical trials have demonstrated the superior performance of ADCs over traditional chemotherapy in various cancer types, including bladder, breast, and lung cancers. For example, the combination of enfortumab vedotin and pembrolizumab has shown a near doubling of overall survival rates in bladder cancer patients compared to standard treatments. This success underscores the growing potential of ADCs to become a primary treatment modality for cancers that were previously difficult to manage.
Segment Analysis:
By product, Kadcyla dominated the ADC market with a 28% market share in 2023, driven by its established efficacy in treating HER2-positive breast cancer. Its dominance is further supported by the increasing number of regulatory approvals for ADCs specifically targeting breast cancer.
By disease type, breast cancer was the leading segment, accounting for 44% of the market share in 2023. The dominance of this segment is attributed to the high adoption rate of ADCs among breast cancer patients and the large number of clinical trials focused on breast cancer ADCs. Additionally, the increasing approval of ADCs for other cancers, such as blood, lung, cervical, and ovarian cancers, signifies a promising trend toward the diversification of ADC applications.
Antibody Drug Conjugates [ADC] Market Key Segmentation:
By Product
- Kadcyla
- Enhertu
- Adcetris
- Padcev
- Trodelvy
- Polivy
- Other
By Disease Type
- Breast Cancer
- Blood cancer
- Others
By Linker Type
- Non-cleavable
- Cleavable
By Target
- HER2
- CD22
- CD30
- Others
By Payload Type
- MMAE/ auristatin
- Calicheamicin
- Maytansinoids
- Others
Key Regional Developments:
North America held the largest market share of 48.33% in 2023, a trend expected to continue throughout the forecast period. The dominance is driven by a strong pipeline of new ADCs and a rapid pace of regulatory support in the region. The U.S., in particular, has seen significant investment in ADC research and development, with major pharmaceutical companies leading the charge. Meanwhile, the Asia Pacific region is poised for the fastest growth, spurred by a rising cancer incidence and increasing acceptance of ADCs as a viable treatment option. The recent launch of Zydus' biosimilar Ujivra in the region is expected to further accelerate market growth. As more patients and healthcare providers in Asia Pacific embrace ADCs, the region is likely to become a key player in the global ADC market.
Recent Developments:
- In July 2024, Ipsen and Foreseen Biotechnology announced an exclusive global licensing agreement for FS001, a next-generation antibody-drug conjugate (ADC), marking a significant milestone in cancer treatment advancements.
- AstraZeneca continues to lead the ADC market with its established ADC trastuzumab deruxtecan, which is approved for multiple indications. The company is also actively developing a new ADC, datopotamab deruxtecan. In May 2024, AstraZeneca announced a substantial USD 1.5 billion investment to establish a dedicated ADC manufacturing facility in Singapore, underscoring its commitment to the field.
Buy an Enterprise-User PDF of Antibody Drug Conjugates [ADC] Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/4421
Key Takeaways:
- Comprehensive analysis of the ADC market, including key drivers, restraints, and opportunities.
- Insights into the most dominant product and disease segments, with a focus on market dynamics.
- Regional analysis highlighting the leading markets and regions with the highest growth potential.
- Evaluation of recent developments and strategic moves by key players in the ADC market.
- Detailed understanding of the competitive landscape and emerging trends in the ADC sector.
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Antibody Drug Conjugates (ADC) Market Segmentation, by Product
8. Antibody Drug Conjugates (ADC) Market Segmentation, By Disease Type
9. Antibody Drug Conjugates (ADC) Market Segmentation, By Linker Type
10. Antibody Drug Conjugates (ADC) Market Segmentation, By Target
11. Antibody Drug Conjugates (ADC) Market Segmentation, By Payload Type
12. Regional Analysis
13. Company Profiles
14. Use Cases and Best Practices
15. Conclusion
Access Complete Report Details of Antibody Drug Conjugates (ADC) Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/reports/antibody-drug-conjugates-market-4421
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
